Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of ALN-TTR01 in patients with transthyretin (TTR) mediated amyloidosis (ATTR).


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Amyloidosis
  • Transthyretin Mediated Amyloidosis (ATTR)

NCT number NCT01148953
Study type Interventional
Source Alnylam Pharmaceuticals
Contact
Status Completed
Phase Phase 1
Start date June 2010
Completion date February 2012